

### REMARKS

Claims 9-46 and 53-97 are pending. Claims 66-68 and 93-97 were elected with traverse for examination in this application; the reasons for traversal were provided on January 27, 2005. In response to the Examiner's requirement for an election of species, the INPROL which is Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val (SEQ ID NO:1) and the opiate compound which is naloxone were elected. The elected species of INPROL reads on claims 66-68 and 93-97; the elected species of opiate compound reads on claims 66-68 and 93-97. Applicants reserve the right to prosecute non-elected subject matter in a further patent application.

Sequence identifiers are corrected. The amino acid sequences of original SEQ ID NO:36 are recited in the present SEQ ID NOS:36-39.

The attached paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. It is respectfully submitted that they comply with 37 CFR § 1.821 et seq. Otherwise, prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.

Applicants earnestly solicit an early and favorable examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

Gary R. Tanigawa  
Reg. No. 43,180

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100